Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin

Trial Profile

Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Trilaciclib (Primary) ; Carboplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Proof of concept
  • Sponsors G1 Therapeutics
  • Most Recent Events

    • 09 Aug 2017 According to a G1 Therapeutics media release, the company expects topline data from this trial in the first quarter of 2018.
    • 07 Aug 2017 Planned End Date changed from 1 Mar 2018 to 1 Jul 2019.
    • 07 Aug 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top